- Accelerating Treatment Development
Lead
ing the
Leading the
Development of
Targeted Therapies in Cancer
Our team is dedicated to the development of innovative antibody treatments designed to challenge and revolutionize cancer care.
We are hiring
We are announcing a PhD position within the MSCA’s doctoral network ACHILLES.
ACHILLES (Advancing in the challenge of improving lymphoma and leukemia survival) is a Marie Skłodowska Curie Action (MSCA) Doctoral Network (DN) financed by the European Commission within Horizon Europe.
As a PhD student in the European ACHILLES network, you will be part of a dynamic, international team. ACHILLES will train 16 PhD students with the goal of A) developing advanced experimental models, B) gaining new insights into the mechanisms underlying leukemia and lymphoma biology, and C) developing and validating new therapies for the treatment of hematological malignancies.
ACHILLES will bring together leading players in Europe in the fields of immunotherapy, functional genomics, chromatin regulation, AI, and leukemia/lymphoma. You will be employed at Lead Biologics and you will conduct your own research project at Lund University (DC14). To broaden your expertise, you will also complete internships at other ACHILLES partner organizations.
Please read more here: https://achilles-dn.eu/
How to apply: https://careers.carrerasresearch.org/jobs/6790802-vac_117_2025-doctoral-candidates-achilles-msca-doctoral-network
Explore our innovative science
Cutting-edge Therapeutic Solutions
We leverage scientific innovation and expertise to create groundbreaking first-in-class cancer treatments. We’re committed to not just fighting cancer, but also to improving the quality of life for patients.
Discovery of Novel Targets
We identify and explore novel targets based on academic excellence to develop new first-in-class treatment options.
Development of Drug Candidates
We develop therapeutics antibodies against cancer.
By combining expertise in recombinant antibody technology and state-of-the-art experimental models we provide proof-of-concept for novel treatment.
Collaboration Drives Progress
We believe in academic and industrial collaborations at an early stage.
By working with excellent partners, our projects are brought to the benetfit of patients in the fastest and most efficient way.
Learn More About Our Drug Development Programs
New targets are needed...
Cancer is a leading cause of death worldwide, accounting for nearly 10 million deaths yearly, or nearly one in six deaths.
...to efficiently treat where we fail today.
Discover with Lead Biologics